|Bid||1.9750 x 1214500|
|Ask||1.9900 x 938700|
|Day's range||1.9600 - 2.0000|
|52-week range||0.9950 - 2.5300|
|Beta (5Y monthly)||1.35|
|PE ratio (TTM)||N/A|
|Earnings date||24 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Neuren Pharmaceuticals Limited (ASX: NEU) has received clear and constructive guidance from the FDA Office of Neuroscience in pre-IND meetings for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman and Pitt Hopkins syndromes. All three syndromes are serious neurological disorders that emerge in early childhood and have no approved medicines.